Irish medical device company Medtronic has launched Solitaire X, a revascularisation device intended to treat patients with acute ischemic stroke, in the US.

The device can be used to mechanically remove blood clots from blocked vessels in the brain. This helps restore blood flow in acute ischemic stroke patients with large vessel occlusion.

Stroke, which causes approximately six million deaths annually, is considered as the second leading cause of death worldwide. The condition is also the leading cause of serious, long-term disability in the US. A stroke occurs every 40 seconds in America, and is responsible for a death every four minutes, affecting around 795,000 people a year.

Solitaire X is the company’s fourth generation device. It is equipped with an optimised delivery system to enhance efficiency along with the technical features of its predecessor revascularisation devices.

“Solitaire X 6×40 device combined with Phenom 21 catheter provides smooth navigation especially when working with complicated anatomy.”

Medtronic Neurovascular business vice-president and general manager Stacey Pugh said: “Our commitment to enable physicians to improve outcomes for stroke patients worldwide will always be our motivation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The net result of that commitment is the launch of a 4th generation device – Solitaire X – which marks ten years of innovation in stroke therapy.”

The company has also launched a 160cm microcatheter, dubbed Phenom 21 Catheter, for the delivery of all sizes of the latest revascularisation device.

In combination with the microcatheter, Solitaire X is expected to offer a low clot crossing profile and enable smooth delivery to occlusions in distal vessels as small as 2mm.

UCLA professor of radiology and neurosurgery Dr Reza Jahan said: “Medtronic continues to deliver technological innovations to advance stroke treatment. As a long-time Solitaire user, I am impressed with the ease of the Solitaire X delivery.

“I find that Solitaire X 6×40 device combined with Phenom 21 catheter provides smooth navigation especially when working with complicated anatomy.”